2002, 2018

New partnership anticipated to transform the diagnosis of febrile ARIs at the point-of-care

Atomo Diagnostics is delighted to announce it's commercial and development partnership with US biotechnology company, RPS Diagnostics. In a joint Press Announcement, the companies have shared plans to create next generation FebriDx® tests that are anticipated to [...]

2301, 2018

Strategic Partnership Announcement: Atomo Diagnostics and Access Bio

Today, Atomo Diagnostics and Access Bio Inc. jointly announced a strategic partnership to leverage the respective strengths of both companies and expand point of care HIV testing in global markets. Atomo will supply its award-winning AtomoRapid™ lateral [...]

612, 2017

Atomo HIV Self Test approved by Expert Review Panel

Atomo Diagnostics' CEO, John Kelly, today announced that the Atomo HIV Self Test has been approved by the World Health Organisation’s Expert Review Panel for Diagnostics (ERP-D); a special process determined by Unitaid and The Global [...]

1010, 2017

CE Marking granted for Atomo HIV Self Test

Atomo Diagnostics' CEO John Kelly announced today that the Atomo HIV Self Test has been granted CE Marking by a European Union Notified Body. The company is now actively engaging with commercialisation and distribution partners to make the test [...]